1218 related articles for article (PubMed ID: 24598441)
1. Dynamic contrast-enhanced micro-computed tomography correlates with 3-dimensional fluorescence ultramicroscopy in antiangiogenic therapy of breast cancer xenografts.
Pöschinger T; Renner A; Eisa F; Dobosz M; Strobel S; Weber TG; Brauweiler R; Kalender WA; Scheuer W
Invest Radiol; 2014 Jul; 49(7):445-56. PubMed ID: 24598441
[TBL] [Abstract][Full Text] [Related]
2. Three-dimensional Dynamic Contrast-enhanced US Imaging for Early Antiangiogenic Treatment Assessment in a Mouse Colon Cancer Model.
Wang H; Hristov D; Qin J; Tian L; Willmann JK
Radiology; 2015 Nov; 277(2):424-34. PubMed ID: 26020439
[TBL] [Abstract][Full Text] [Related]
3. Dynamic contrast-enhanced micro-CT on mice with mammary carcinoma for the assessment of antiangiogenic therapy response.
Eisa F; Brauweiler R; Hupfer M; Nowak T; Lotz L; Hoffmann I; Wachter D; Dittrich R; Beckmann MW; Jost G; Pietsch H; Kalender WA
Eur Radiol; 2012 Apr; 22(4):900-7. PubMed ID: 22071777
[TBL] [Abstract][Full Text] [Related]
4. Low-molecular contrast agent dynamic contrast-enhanced (DCE)-MRI and diffusion-weighted (DW)-MRI in early assessment of bevacizumab treatment in breast cancer xenografts.
Moestue SA; Huuse EM; Lindholm EM; Bofin A; Engebraaten O; Mælandsmo GM; Akslen LA; Gribbestad IS
J Magn Reson Imaging; 2013 Nov; 38(5):1043-53. PubMed ID: 23908122
[TBL] [Abstract][Full Text] [Related]
5. Developing DCE-CT to quantify intra-tumor heterogeneity in breast tumors with differing angiogenic phenotype.
Cao M; Liang Y; Shen C; Miller KD; Stantz KM
IEEE Trans Med Imaging; 2009 Jun; 28(6):861-71. PubMed ID: 19150783
[TBL] [Abstract][Full Text] [Related]
6. Dynamic contrast-enhanced computed tomography imaging biomarkers correlated with immunohistochemistry for monitoring the effects of sorafenib on experimental prostate carcinomas.
Cyran CC; von Einem JC; Paprottka PM; Schwarz B; Ingrisch M; Dietrich O; Hinkel R; Bruns CJ; Clevert DA; Eschbach R; Reiser MF; Wintersperger BJ; Nikolaou K
Invest Radiol; 2012 Jan; 47(1):49-57. PubMed ID: 21934514
[TBL] [Abstract][Full Text] [Related]
7. Cluster analysis of quantitative parametric maps from DCE-MRI: application in evaluating heterogeneity of tumor response to antiangiogenic treatment.
Longo DL; Dastrù W; Consolino L; Espak M; Arigoni M; Cavallo F; Aime S
Magn Reson Imaging; 2015 Jul; 33(6):725-36. PubMed ID: 25839393
[TBL] [Abstract][Full Text] [Related]
8. Multispectral fluorescence ultramicroscopy: three-dimensional visualization and automatic quantification of tumor morphology, drug penetration, and antiangiogenic treatment response.
Dobosz M; Ntziachristos V; Scheuer W; Strobel S
Neoplasia; 2014 Jan; 16(1):1-13. PubMed ID: 24563615
[TBL] [Abstract][Full Text] [Related]
9. GPU-accelerated nonparametric kinetic analysis of DCE-MRI data from glioblastoma patients treated with bevacizumab.
Hsu YH; Ferl GZ; Ng CM
Magn Reson Imaging; 2013 May; 31(4):618-23. PubMed ID: 23200680
[TBL] [Abstract][Full Text] [Related]
10. Three-dimensional contrast enhanced ultrasound score and dynamic contrast-enhanced magnetic resonance imaging score in evaluating breast tumor angiogenesis: correlation with biological factors.
Jia WR; Chai WM; Tang L; Wang Y; Fei XC; Han BS; Chen M
Eur J Radiol; 2014 Jul; 83(7):1098-1105. PubMed ID: 24794865
[TBL] [Abstract][Full Text] [Related]
11. Assessing breast cancer angiogenesis in vivo: which susceptibility contrast MRI biomarkers are relevant?
Kim E; Cebulla J; Ward BD; Rhie K; Zhang J; Pathak AP
Magn Reson Med; 2013 Oct; 70(4):1106-16. PubMed ID: 23225578
[TBL] [Abstract][Full Text] [Related]
12. Antiangiogenic and radiation therapy: early effects on in vivo computed tomography perfusion parameters in human colon cancer xenografts in mice.
Ren Y; Fleischmann D; Foygel K; Molvin L; Lutz AM; Koong AC; Jeffrey RB; Tian L; Willmann JK
Invest Radiol; 2012 Jan; 47(1):25-32. PubMed ID: 22178893
[TBL] [Abstract][Full Text] [Related]
13. Intra-Animal Comparison between Three-dimensional Molecularly Targeted US and Three-dimensional Dynamic Contrast-enhanced US for Early Antiangiogenic Treatment Assessment in Colon Cancer.
Wang H; Lutz AM; Hristov D; Tian L; Willmann JK
Radiology; 2017 Feb; 282(2):443-452. PubMed ID: 27490690
[TBL] [Abstract][Full Text] [Related]
14. Water exchange-minimizing DCE-MRI protocol to detect changes in tumor vascular parameters: effect of bevacizumab/paclitaxel combination therapy.
Zhu W; Kato Y; Artemov D
MAGMA; 2014 Apr; 27(2):161-70. PubMed ID: 23807596
[TBL] [Abstract][Full Text] [Related]
15. Combining dynamic contrast enhanced magnetic resonance imaging and microvessel density to assess the angiogenesis after PEI in a rabbit VX2 liver tumor model.
Chen J; Qian T; Zhang H; Wei C; Meng F; Yin H
Magn Reson Imaging; 2016 Feb; 34(2):177-82. PubMed ID: 26518059
[TBL] [Abstract][Full Text] [Related]
16. Dynamic contrast-enhanced magnetic resonance imaging of tumors: preclinical validation of parametric images.
Egeland TA; Simonsen TG; Gaustad JV; Gulliksrud K; Ellingsen C; Rofstad EK
Radiat Res; 2009 Sep; 172(3):339-47. PubMed ID: 19708783
[TBL] [Abstract][Full Text] [Related]
17. Dynamic contrast-enhanced ultrasound parametric maps to evaluate intratumoral vascularization.
Pitre-Champagnat S; Leguerney I; Bosq J; Peronneau P; Kiessling F; Calmels L; Coulot J; Lassau N
Invest Radiol; 2015 Apr; 50(4):212-7. PubMed ID: 25275834
[TBL] [Abstract][Full Text] [Related]
18. Quantification of perfusion and permeability in multiple sclerosis: dynamic contrast-enhanced MRI in 3D at 3T.
Ingrisch M; Sourbron S; Morhard D; Ertl-Wagner B; Kümpfel T; Hohlfeld R; Reiser M; Glaser C
Invest Radiol; 2012 Apr; 47(4):252-8. PubMed ID: 22373532
[TBL] [Abstract][Full Text] [Related]
19. Imaging anti-angiogenic treatment response with DCE-VCT, DCE-MRI and DWI in an animal model of breast cancer bone metastasis.
Bäuerle T; Bartling S; Berger M; Schmitt-Gräff A; Hilbig H; Kauczor HU; Delorme S; Kiessling F
Eur J Radiol; 2010 Feb; 73(2):280-7. PubMed ID: 19070445
[TBL] [Abstract][Full Text] [Related]
20. 18F-FDG small-animal PET/CT differentiates trastuzumab-responsive from unresponsive human breast cancer xenografts in athymic mice.
McLarty K; Fasih A; Scollard DA; Done SJ; Vines DC; Green DE; Costantini DL; Reilly RM
J Nucl Med; 2009 Nov; 50(11):1848-56. PubMed ID: 19837760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]